Oncology and other specialty therapies continue to get more and more expensive for payers, placing immense financial pressure on the HCP. The percentage increase in worldwide spending on oncology medications went up by double digits every year between 2013 and 2018, and reached nearly $150 billion in 2018. Modern cancer therapies significantly improve disease outlook, but with a tremendous cost of treatment.